RecruitingPhase 2NCT05472337

Effect of Colchicine on Coronary Reperfusion in Patients With Acute Coronary Syndrome

Sponsor

Pontificia Universidad Catolica de Chile

Enrollment

50 participants

Start Date

Aug 1, 2022

Study Type

INTERVENTIONAL

Conditions

Acute Coronary Syndrome

Summary

This randomized clinical trial will determine the treatment effect of colchicine (1.5 mg loading dose and 0.5 mg daily thereafter) for 6 weeks on microvascular coronary reperfusion and infarct size in patients with acute coronary syndrome.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Colchicine for people with acute coronary syndrome. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGColchicine

Oral colchicine (1 mg loading dose followed by 0.5 mg 1 hour later, administered 6 to 24 hours before angioplasty, followed by 0.5 mg (1 comp.) per day for 6 weeks.

Locations(1)

Hospital Clínico Pontificia Universidad Catolica de Chile

Santiago, Santiago Metropolitan, Chile

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05472337

Related Trials

Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions

NCT072582902 locations

A Polypill for Acute Coronary Syndrome

NCT070323892 locations

Effectiveness of a Resilience-Based Rehabilitation Program for Patients With Coronary Heart Disease

NCT063328591 location

Revascularization Strategies in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS) and Severe Coronary Artery Disease

NCT013113239 locations

Potassium-Competitive Acid Blocker Versus pROton-Pump Inhibitor for GastroproTECTion Strategies In Patients at High Gastro-Intestinal Bleeding Risk Receiving Antithrombotic Therapy

NCT0441658145 locations